LEXICON
No.125 September 10, 2012

GPMSP (good post-marketing surveillance practice)
医薬品の市販後調査の基準
GPSP (good post-marketing study practice)
医薬品の製造販売後の調査及び試験の実施の基準
GVP (good vigilance practice)
医薬品、医薬部外品、化粧品及び医療機器の製造販売後安全管理の基準

The amended Pharmaceutical Affairs Law (PAL; 薬事法), which went into full effect on April 1, 2005, divided post-marketing surveillance (PMS; 市販後調査), which had been conducted in accordance with the GPMSP (good post-marketing surveillance practice) standards (医薬品の市販後調査の基準), into 1) post-marketing drug...

To read the full story

LEXICON

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…